ANTIGEN-ANTIBODY COMPLEXES IN BREAST CANCER

本研究的目的是检测可溶性抗原-抗体复合体。 C1q结合放射免疫法测定乳腺癌患者血清 细胞放射免疫测定法和(兔)类风湿因子测定法。血清 样本将从乳腺癌患者、纤维囊性乳房 疾病患者和乳腺癌家属以及来自适当的健康人士 控制个人。将对乳腺癌患者进行纵向跟踪 用于评估治疗的反应，以确定预后 和监测价值的化验。高危人群(纤维囊性乳腺 疾病和乳腺癌家族)也将被跟踪，以便评估 免疫复合体检测的诊断潜力。抗原-抗体 还应从血清和体液(胸膜)中分离出复合体 乳腺癌患者的分子排斥层析)， 蛋白A亲和层析及亲和介质免疫吸附 Ig G的Fc结构域。此外，分离的免疫复合体将被 在变性最小的条件下解离。解离的抗原是 具有生物化学和免疫学特征。异种生物抗血清将 用解离抗原(S)和分离的复合体以及 将含有表面结合免疫复合体的Raji细胞注射到 兔对人免疫球蛋白产生耐受性，并研究其重组能力 解离的抗原并与恶性乳腺组织结合。离体 抗体依赖细胞介导的细胞毒性，淋巴细胞有丝分裂， PHA诱导的淋巴细胞转化和LAI测定也可用于 研究抗体-抗原复合体可能的生物学功能。此外， 将开发一种放射免疫分析方法，可用于早期检测和 乳腺癌治疗效果监测。

The objective of this study is to assay soluble antigen-antibody complexes in serum of patients with breast cancer using C1q binding radioimmunoassay, Raji cell radioimmunoassay, and (rabbit) rheumatoid factor assay. The serum specimens will be obtained from breast cancer patients, fibrocystic breast disease patients and breast cancer families as well as from appropriate healthy control individuals. The breast cancer patients will be longitudinally followed for evaluation of the response to treatment in order to determine the prognostic and monitoring values of the assay. The high risk groups (fibrocystic breast disease and breast cancer families) are also to be followed in order to evaluate the diagnostic potential of the immune complex assay. The antigen-antibody complexes are also to be isolated from the serum and body fluids (pleural effusion) of breast cancer patients by molecular exclusion chromatography, protein A affinity chromatography and immunoadsorption using affinity media to the Fc domain of IgG. Further, the isolated immune complexes will be dissociated under the least denaturing conditions. The dissociated antigens are to be characterized biochemically and immunologically. Xenobiotic antisera will be raised with the dissociated antigen(s) and with isolated complexes as well as with the Raji cells containing surface-bound immune complexes injected into rabbits made tolerant to human IgG, and studied by their ability to recombine the dissociated antigen and to bind malignant breast tissues. In vitro antibody-dependent cell-mediated cytotoxicity, lymphocyte mitogenesis, PHA-induced lymphocyte blastogenesis and LAI assays are also to be performed to study the possible biological function of antibody-antigen complexes. Further, a radioimmunoassay will be developed which may be of use in early detection and monitoring of efficacy of therapy for breast cancer.